Executive Summary: Key Legal and Evidentiary Issues

• Alleged negligent design of Advanced Bionics cochlear implants, causing fluid ingress, electrical failure, and the need for invasive revision surgery for patients implanted in Canada (excluding Quebec) between 2016 and February 18, 2020.
• Dispute over whether causation and damages can be determined on a class-wide basis given complex, individualized medical histories and symptoms of putative class members.
• Recognition at the pleadings stage of viable causes of action in negligent design, failure to warn, and a novel but arguable duty to recall, while striking negligent manufacturing as a basis of liability.
• Refinement of the proposed class to include only patients whose cochlear implants suffered objectively verifiable “hard failures” and who underwent revision surgery, along with derivative Family Law Act claimants.
• Determination that numerous liability and damages issues, including potential punitive damages and health-care cost recovery claims, can proceed as common issues despite differing provincial statutes.
• Application of the new predominance requirement under s. 5(1.1)(b) of the Class Proceedings Act, with the court limiting recoverable damages to predominantly medical and monitoring harms so that common issues predominate and certification is preferable.

Background and factual context

The case involves a proposed national class action (excluding Quebec) brought by Paul Pedersen against several related entities connected to Advanced Bionics cochlear implants. The devices at issue are internal electronic cochlear implants designed to last for a patient’s lifetime and to restore hearing by converting sound to electronic impulses delivered to the auditory nerve. Unlike external hearing aids, these implants require invasive surgery to insert and similarly invasive, risky surgery to remove and replace. The plaintiff alleges that certain Advanced Bionics models were defectively designed, making them prone to ingress of body fluids into the electrode array. This alleged defect leads to short-circuiting and degradation of device performance, ultimately requiring explantation and replacement through further surgery. Evidence before the court suggested that up to approximately half of the defendants’ implants had failed in this manner, and the plaintiff’s expert, Dr. Richard Gurgel, opined that all such devices would eventually fail prematurely, even while emphasizing that each patient requires an individualized medical assessment before any revision surgery. The record shows that Advanced Bionics first acted publicly on these concerns on February 18, 2020, when it voluntarily removed unimplanted devices from the market and sent letters to patients referencing a “device issue” that might affect performance. A further “Urgent Field Action Notification” was sent to healthcare providers on February 21, 2020, describing an increase in device explants or potential explants due to performance issues. Shortly thereafter, Health Canada issued a Type II Medical Device Recall (effective from February 18, 2020) identifying “Device Design” and fluid ingress as the cause; a similar recall was issued by the U.S. FDA, specifying hearing performance degradation due to body fluid entering the device. The recall notices indicated that the manufacturer had discovered a defect during failure analysis of an explanted device in March 2019 and had already developed and obtained regulatory approval for design improvements, yet no warning had been issued to patients or clinicians in the interim. The proposed class period runs from 2016 to February 18, 2020, covering about 250 Canadian patients (outside Quebec), including approximately 50 minors, whose devices were designed, marketed, sold, and serviced by the defendants during that time. Affidavits from Mr. Pedersen and another proposed class member, Patric Boone, describe the profound initial benefit from implantation, followed by deteriorating performance and the eventual need for painful revision surgeries, including psychological and social impacts. However, their medical histories also reveal complex comorbidities and overlapping symptoms, which the defendants argue make individual causation assessments unavoidable and highly individualized.

Allegations and causes of action

The Second Amended Statement of Claim initially advanced several product liability theories: negligent design, negligent manufacturing, failure to warn, and failure to recall. By the time of the certification motion, the plaintiff had abandoned negligent manufacturing and relied on three main negligence-based causes of action. First, negligent design is pleaded on the basis that the defendants were responsible for research, design, manufacturing, distribution, sale, and post-market monitoring, and knew by at least the first quarter of 2019 that the devices were dangerously defective and prone to fluid ingress, yet continued to market and distribute them until February 18, 2020. The plaintiff relies on clinical studies, experience with predecessor devices that had similar hermeticity and fluid-ingress issues, post-market servicing experience, and clinical trial failures to support the allegation that the design rendered the implants unfit and unsafe for their intended use. Second, the plaintiff pleads a failure to warn. He alleges that once the defendants knew or ought to have known of the design defect and associated risks, they had a continuing duty to warn patients and healthcare providers, both as to inherent risks and as to subsequently discovered dangers, so that patients could be monitored and harmful effects identified earlier. The court recognizes that a failure to warn claim can, in principle, supplement—not replace—the design negligence claim by addressing incremental harms caused by delayed disclosure and delayed medical intervention. Third, the plaintiff asserts a failure (or duty) to recall, arguing that once the defendants knew the devices were defective and harmful, they were obliged to act prudently by initiating a timely recall, rather than leaving defective products in circulation until regulators intervened. The court notes that a stand-alone duty to recall has not yet been specifically recognized in Canadian case law but accepts that this is a novel yet arguable claim that should be tested on a full evidentiary record rather than struck at the pleadings stage. The plaintiff also alleges statutory breaches under the federal Food and Drugs Act and Medical Devices Regulations, particularly duties to identify, reduce, and communicate risks associated with the devices, and seeks to use those statutory standards as relevant evidence of the standard of care owed at common law. Beyond direct claims by implant recipients, the claim includes derivative claims by family members under Ontario’s Family Law Act and similar legislation in other provinces and territories, as well as subrogated health-care cost recovery claims by provincial and territorial health insurers relating to surgeries, monitoring, and treatment prompted by device failures.

Defence position and individualized causation concerns

The defendants acknowledge that there have been instances of device failure and revision surgery but stress that each patient’s medical profile is unique. They rely on expert evidence from Dr. Jeffrey P. Harris, who emphasizes that cochlear implant performance and outcomes are shaped by patient-specific factors such as the cause and duration of deafness, age, other health conditions, and overall medical status. Using the detailed medical histories of Mr. Boone and Mr. Pedersen, the defendants argue that many of the claimed symptoms could stem from comorbidities unrelated to the implants, and that even symptoms the patients subjectively connect to the devices may persist after revision surgery, casting doubt on causation. The defendants thus contend that individual causation and damages questions will swamp any common issues and that the action fails the predominance requirement introduced in s. 5(1.1)(b) of the Class Proceedings Act. They also challenge the legal viability of the failure-to-warn and duty-to-recall theories, arguing that design negligence subsumes such obligations and that Canadian law does not recognize a separate duty to recall. Furthermore, they argue that alleged breaches of regulatory statutes do not, by themselves, ground civil liability, and that damages, especially for personal injury, lifestyle impacts, and economic loss, are inherently individualized and unsuited to aggregate determination.

Certification requirements and class definition

The court methodically analyzes the statutory certification requirements under s. 5(1) of the Class Proceedings Act, along with the newer predominance requirement in s. 5(1.1)(b). As to cause of action, the court applies the “plain and obvious”/“no reasonable prospect of success” standard and finds that the pleading supports viable claims for negligent design, failure to warn, and failure to recall (while noting that negligent manufacturing has been abandoned). The novelty of the alleged duty to recall is not a bar at this procedural stage; the court stresses that unsettled law and slim odds of success are not reasons to strike a claim before trial. Regarding an identifiable class, the plaintiff’s original definition encompassed all persons implanted with the specified device models in Canada (excluding Quebec) and their Family Law Act claimants. The court accepts that membership is objectively verifiable through medical and hospital records and defendants’ own databases but holds the definition to be overbroad because it includes people whose devices have not yet failed and thus may not have suffered any compensable loss. Relying on higher-court authority that negligent conduct without materialized damage is not actionable, the court narrows the class to those whose devices have suffered “hard failures”—objectively verifiable device malfunctions attributable to fluid ingress and detectable through impedance and electrical testing—and who have undergone revision surgery. The derivative Family Law Act and equivalent claims remain properly defined, given longstanding acceptance of such derivative classes in medical device actions. With this amendment, the class definition meets s. 5(1)(b).

Common issues and statutory framework

The plaintiff proposes a detailed list of common issues addressing defectiveness, negligent design, duty to warn, duty to recall, statutory standards, liability to family members and health insurers, and various heads of damages, including aggregate and punitive damages. The court emphasizes that at certification it asks only whether there is some basis in fact for treating these questions as common, not whether the plaintiff will win them on the merits. The defendants largely accept that generalized questions about whether the devices were defective and negligently designed (including research and testing aspects) are common, though they successfully insist on deleting “manufacturing” from one question, since that claim is no longer pursued. The court sees no harm in a general question about duty of care as a logical starting point. It then accepts that questions concerning when the defendants knew of the defects, whether and when duties to warn and recall arose, and whether those duties were breached, are appropriate common issues tied to the pleaded causes of action. The court rejects the argument that Family Law Act and related provincial family-compensation issues are too “theoretical” or individualized, explaining that the existence and scope of such legislative rights can be determined in common, even if quantification will later vary by family. Similarly, alleged breaches of the Food and Drugs Act and Medical Devices Regulations, while not automatically dispositive of liability, are relevant to the standard of care and thus support a common issue. On damages, the court distinguishes entitlement from quantification. It concludes that whether class members are prima facie entitled to general damages, punitive damages, and certain categories of pecuniary loss can be addressed on a common basis, even if later individualized assessments are needed. It also accepts common issues about whether class members are “insured persons” under various federal and provincial health statutes and whether the defendants must compensate health insurers for care costs, noting that national class actions can manage provincial statutory variations without losing core commonality. With the deletion of “manufacturing” from one question, the court ultimately approves the full set of proposed common issues.

Predominance, preferability, and limitations on damages

The most contested aspect of the motion centered on whether a class action is the preferable procedure and whether common issues predominate over individual issues, as now required by s. 5(1.1)(b). The court acknowledges that this new predominance language raises the bar somewhat beyond the earlier formulation but declines to import U.S. jurisprudence wholesale. Instead, it focuses on ensuring that the common issues—taken together—constitute the core of the litigation in terms of complexity, scope, and judicial resources. The defendants argue that once the detailed medical and socio-economic circumstances of each patient are considered, individual trials on causation and damages will dominate. The court accepts that the plaintiff’s initial framing risked that outcome, particularly if every aspect of each patient’s employment loss, psychological harm, and social disruption had to be litigated individually. To address this, the plaintiff commits to significant narrowing of the claims. The class is limited, as noted, to individuals with hard device failures who underwent revision surgery, which focuses causation on an objectively verified defect and its direct consequences. Further, the plaintiff confines the class’s aggregate damages claim to a base level of harm suffered in common by all such patients: essentially, the bodily injury and medical consequences associated with device failure and necessary revision surgery. While recognizing that some individualized medical-related damages (such as further monitoring, screening, and strictly medical general damages) will still need assessment, the court explicitly excludes broader socio-economic and lifestyle consequences from the post–common issues stage. In effect, the litigation will concentrate on direct medical harms and related costs traceable to the defective design and revision procedures, plus potential punitive damages based on the defendants’ knowledge and conduct. With these limitations, the court concludes that the common issues will overwhelmingly define the case and that any residual individual inquiries will be relatively minor and manageable. On that basis, both the traditional “preferable procedure” test and the new predominance requirement are satisfied.

Representative plaintiff and litigation plan

The defendants do not contest Mr. Pedersen’s suitability as representative plaintiff, and the court is satisfied that he is informed, engaged, and free from conflicts with other class members. The main challenge is directed at the litigation plan, which is criticized as underestimating the complexity of individual causation and damages issues and as risking unfairly summary procedures (for example, relying primarily on claims forms and limited opportunities for cross-examination). The court points out that the certification-related narrowing of the class, claims, and damages categories significantly reduces the complexity of individual issues. Post–common issues processes can then be designed under s. 25 of the Class Proceedings Act to resolve residual individual medical-related questions efficiently but fairly, drawing on documentary evidence and limited, targeted procedures where appropriate. Recognizing that any litigation plan is a work in progress, the court expresses confidence that remaining procedural details can be refined after the common issues trial in light of the findings and with continued attention to both efficiency and fairness.

Outcome and relief granted

In the result, the Superior Court of Justice in Ontario certifies the action as a class proceeding. The court confirms Paul Pedersen as representative plaintiff and appoints his counsel as class counsel. It approves the causes of action in negligent design, failure to warn, and failure to recall; adopts a narrowed class definition limited to implant recipients whose devices have suffered hard failures and who have undergone revision surgery, along with derivative Family Law Act claimants; and settles a robust list of common issues, including potential punitive damages and health insurer recovery claims. The court also explicitly limits the scope of recoverable damages to a base level of medical and monitoring harms and related costs so that common issues predominate under the amended certification regime. On the question of monetary relief, this certification decision does not decide liability or fix any damages, costs, or compensation; it merely allows the class action to proceed. The successful party on this motion is the plaintiff and proposed class, but the total monetary award, including any damages, costs, or other financial recovery in their favor, cannot yet be determined because no final adjudication on liability or quantum has been made.